Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 19;19(1):1069.
doi: 10.1186/s12879-019-4687-7.

Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis

Youness Mechal  1   2 , Elmostafa Benaissa  3   4 , Nadia El Mrimar  3   4 , Yassine Benlahlou  3   4 , Fatna Bssaibis  4 , Adil Zegmout  5 , Mariama Chadli  4 , Yashpal S Malik  6 , Nadia Touil  7 , Ahmed Abid  5 , Adil Maleb  8 , Mostafa Elouennass  3   4
Affiliations

Evaluation of GeneXpert MTB/RIF system performances in the diagnosis of extrapulmonary tuberculosis

Youness Mechal et al. BMC Infect Dis. .

Abstract

Background: Tuberculosis represents a serious public health problem and a significant diagnostic and therapeutic challenge worldwide. Molecular diagnostic techniques are crucial in the World Health Organization's new tuberculosis control strategy. This study aims to evaluate the performance of GeneXpert MTB/RIF (Cepheid Sunnyvale, CA, United States) in diagnosis of extra-pulmonary tuberculosis then compare it's performance in detecting Rifampicin resistance to GenoType MTBDRplus (HAIN Life Sciences, Nehren, Germany).

Methods: Samples from pulmonary and/or extra-pulmonary origins were analysed in a 21 months retrospective study. Samples were sent to the bacteriology laboratory for Mycobacterium tuberculosis detection using conventional bacteriological and molecular methods (GeneXpert MTB/RIF and MTBDRplus). Sensitivity and specificity were calculated for the stained smear and GeneXpert according to culture (Gold Standard) as well as for GeneXpert MTB/RIF in both negative and positive microscopy tuberculosis cases. Data's statistical analysis was performed with SPSS13.0 software.

Results: Seven hundred fourteen patients' samples were analysed; the average age was 47.21 ± 19.98 years with a male predominance (66.4%). Out of 714 samples: 285 were from pulmonary and 429 were from extra-pulmonary origins. The positivity rates for microscopy, GeneXpert MTB/RIF and culture were 12.88, 20.59 and 15.82%, respectively. These rates were 18.9, 23.85 and 20.35% for pulmonary samples and 9.71, 18.41 and 12.82% for extra-pulmonary samples, respectively. The sensitivity and specificity of GeneXpert MTB/RIF were almost the same in both pulmonary and extra-pulmonary samples (78.2 and 90.4%) and (79,3 and 90.3%) respectively. Rifampicin resistance rate found by GeneXpert MTB/RIF was 0.84%. Comparison of Rifampicin resistance obtained by GeneXpert MTB/RIF and Genotype MTBDRplus, showed 100% agreement between the two techniques for studied samples.

Conclusions: This confirms GeneXpert MTB/RIF advantage for tuberculosis diagnosis, particularly extra-pulmonary tuberculosis with negatively stained smear. The performance of GeneXpert and Genotype MTBDRplus are similar in detection of Rifampicin resistance. However, variability of detection performance according to tuberculosis endemicity deserves more attention in the choice of screening techniques of Rifampicin resistance, hence the interest of conducting comparative studies of detection performance under low and medium endemicity on large samples of tuberculosis populations.

Keywords: Extra-pulmonary tuberculosis; Molecular diagnostic techniques; Morocco; Multidrug-resistance; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Distribution of samples included in our study by type and by sampling site
Fig. 2
Fig. 2
Sensitivities of direct examination and GeneXpert MTB/RIF in extra-pulmonary samples
See this image and copyright information in PMC

References

    1. Organisation Mondiale de la Santé Rapport sur la lutte contre la tuberculose dans le monde 2017. Organisation Mondiale de la Santé; 2017. https://www.who.int/tb/publications/global_report/gtbr2017_executive_sum.... Accessed 19 Jan 2019.
    1. World Health Organization . Global tuberculosis Report 2018. S.l.: World Health Organization. 2018.
    1. World Health Organization . Tuberculosis profile - Morocco. 2017.
    1. Purohit M, Mustafa T. Laboratory diagnosis of extra-pulmonary tuberculosis (EPTB) in resource-constrained setting: state of the art, challenges and the need. J Clin Diagn Res. 2015;9:EE01–EE06. - PMC - PubMed
    1. Lee JY. Diagnosis and treatment of Extrapulmonary tuberculosis. Tuberc Respir Dis. 2015;78:47. doi: 10.4046/trd.2015.78.2.47. - DOI - PMC - PubMed

Publication types

MeSH terms